This company has been acquired
Standard BioTools Management
Management criteria checks 2/4
Standard BioTools' CEO is Adam Taich, appointed in Mar 2023, has a tenure of less than a year. directly owns 0.13% of the company’s shares, worth $501.15K. The average tenure of the management team and the board of directors is 2 years and 4 years respectively.
Key information
Adam Taich
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | 0.1% |
| Management average tenure | 2yrs |
| Board average tenure | 4yrs |
Recent management updates
Recent updates
Why Investors Shouldn't Be Surprised By SomaLogic, Inc.'s (NASDAQ:SLGC) P/S
Dec 19
SomaLogic, Inc. (NASDAQ:SLGC) Just Reported, And Analysts Assigned A US$3.93 Price Target
Nov 10SomaLogic, Inc. (NASDAQ:SLGC) Stocks Shoot Up 33% But Its P/S Still Looks Reasonable
Apr 17Downgrade: Here's How Analysts See SomaLogic, Inc. (NASDAQ:SLGC) Performing In The Near Term
Apr 02SomaLogic appoints former Foundation Medicine chief as executive chair
Oct 17SomaLogic acquires Palamedrix to develop next-generation SomaScan Assay
Jul 26We're Hopeful That SomaLogic (NASDAQ:SLGC) Will Use Its Cash Wisely
Jun 06SomaLogic Inc: A Biopharmaceutical Company With An Excellent Upside
Apr 12Calculating The Intrinsic Value Of SomaLogic, Inc. (NASDAQ:SLGC)
Mar 09We Think SomaLogic (NASDAQ:SLGC) Can Easily Afford To Drive Business Growth
Dec 28SomaLogic: The Highest Number Of Proteins Analyzable In A Single Blood Sample In Proteomics
Oct 14CEO
Adam Taich (47 yo)
less than a year
Tenure
Mr. Adam Taich was Executive Vice President of Life Sciences Business Unit at Standard BioTools Inc. (formerly known as SomaLogic, Inc.) since August 2022 until March 28, 2023 and serves as its Interim Chi...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Medical Officer | 15yrs | US$2.55m | 0.085% $ 336.3k | |
| Interim CEO | less than a year | no data | 0.13% $ 501.1k | |
| Interim Chief Accounting Officer | less than a year | no data | no data | |
| Chief Technology Officer | 3yrs | no data | no data | |
| Chief Science Officer | 15yrs | no data | no data | |
| General Counsel | 2yrs | no data | 0.059% $ 232.1k | |
| Chief People Officer | 2yrs | no data | 0.0091% $ 36.0k | |
| Chief Research & Development Officer | 1yr | no data | no data |
2.0yrs
Average Tenure
48.5yo
Average Age
Experienced Management: SLGC's management team is considered experienced (2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Director | 4.3yrs | US$202.07k | 0.030% $ 120.6k | |
| Member of Advisory Board | no data | no data | no data | |
| Independent Director | 3.1yrs | US$197.57k | 0.0018% $ 7.2k | |
| Independent Chairman | less than a year | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | 2.3yrs | US$2.59m | 0.042% $ 164.7k | |
| Independent Director | 4.3yrs | US$204.70k | 0.012% $ 49.2k | |
| Member of Medical Advisory Board | 4yrs | no data | no data | |
| Member of Medical Advisory Board | 4yrs | no data | no data | |
| Member of Medical Advisory Board | 4yrs | no data | no data | |
| Member of Medical Advisory Board | 4yrs | no data | no data | |
| Member of Medical Advisory Board | 4yrs | no data | no data |
4.0yrs
Average Tenure
62.5yo
Average Age
Experienced Board: SLGC's board of directors are considered experienced (4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/01/09 18:45 |
| End of Day Share Price | 2024/01/05 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Standard BioTools Inc. is covered by 3 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kyle Mikson | Canaccord Genuity |
| Brandon Couillard | Jefferies LLC |
| Daniel Brennan | TD Cowen |